Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Vanguard International High Dividend Yield ETF trades at $99.57. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | VYMI | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $101.60 |
52-Week Low | $20.06 | $79.76 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VYMI, Vanguard's International High Dividend Yield ETF, trades at $100.285, up 1.02% today, with a bullish technical outlook from moving averages. The fund offers a diversified portfolio of international dividend stocks with a low 0.07% expense ratio and an estimated yield near 4%, attracting over $2 billion in inflows in 2026 according to The Motley Fool (2026-05-30). Recent news highlights its role in inflation protection and diversification away from U.S. tech concentration.
The outlook for VYMI is positive, driven by strong dividend growth, attractive valuations compared to U.S. markets, and investor demand for international income. Risks include currency fluctuations, economic stagnation in key regions, and competition from other dividend ETFs. Analyst sentiment is generally favorable, emphasizing its defensive qualities in uncertain macroeconomic environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
